- EIB lends Stockholm-based Elekta €100 million to boost treatments for cancer and neurological conditions ranging from tumors in the brain and body to essential tremor and certain forms of epilepsy.
- Loan supports company’s work on improved treatments for millions of cancer and neurological patients worldwide.
- Research to take place mainly in Sweden and the Netherlands between 2026 and 2029.
The European Investment Bank (EIB) is lending up to €100 million to Swedish medical-technology company Elekta AB to advance treatments for a range of cancers and neurological diseases. The EIB loan will support Elekta’s research and development work in radiotherapy, radiosurgery, brachytherapy and the software used to plan and deliver therapies.
Stockholm-based Elekta develops technologies to treat illnesses including brain tumours, breast cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer and essential tremor. The company’s radiotherapy treatments serve more than 2 million patients worldwide a year.
Elekta, which sells its products in more than 120 countries, operates in roughly 40 nations and has about 4,000 employees, plans to invest around €200 million in its research programme between 2026 and 2029. Most of the work will take place in Sweden and the Netherlands, with the EIB loan covering up to half of the investments.
“Europe has world-leading medical-technology companies and we need to make sure they can continue investing and innovating here,” said EIB Vice-President Karl Nehammer. “This financing will support the next generation of cancer and neurological treatments.”
Elekta’s research programme includes new radiotherapy, radiosurgery and brachytherapy systems as well as software for treatment planning, workflow automation and precision delivery. The goal is to improve the accuracy and efficiency of treatments while helping healthcare providers treat more patients as demand for cancer care grows.
“As demand for cancer care continues to grow, healthcare providers are looking for solutions that help them treat more patients while maintaining quality and precision,” said Elekta Chief Financial Officer Klara Eiritz. “This financing provides additional flexibility to support our long-term strategy and continued investments in innovation that improve clinical outcomes, operational efficiency and the patient experience.”
The loan supports the EIB Group’s TechEU programme to strengthen European investment in strategic technologies and innovation. It also contributes to European Union goals for health research, competitiveness and advanced medical technologies.
Background information
EIB Group
The European Investment Bank (EIB) Group is the financing arm of the European Union, owned by the 27 Member States, and one of the largest multilateral development banks in the world. In 2025, the EIB Group signed €100 billion in new financing and advisory services for over 870 high-impact projects under eight core priorities that support EU policy objectives: climate action and the environment, digitalisation and technological innovation, security and defence, territorial cohesion, agriculture and the bioeconomy, social infrastructure, strong global partnerships and the savings and investments union. Beyond long-term loans for large infrastructure, the EIB Group crowds in private investment for high-risk innovative projects and businesses, with a growing role in Europe’s markets for venture debt, venture capital, guarantees and securitisations.
The European Investment Fund (EIF) is the subsidiary of the EIB Group specialised in providing guarantees, securitisation and equity to improve access to finance for small and medium-sized businesses and startups across Europe. Acting as an anchor investor, through its extensive network of partnering banks and investment funds, the EIF mobilises private investment and nurtures the ecosystem of venture capital funds to support innovative European entrepreneurs.
Photos of the EIB Group’s representatives and headquarters, logo files and video B-roll for media use are available here.
Elekta
Elekta is shaping the standard of care, together with healthcare providers, by developing precision radiation medicine that brings advanced radiotherapy into routine clinical practice. Our solutions support consistent, efficient and personalized care, addressing evolving patient needs. Through adaptive radiotherapy, precision treatment delivery and integrated workflows, Elekta supports care teams across a range of clinical settings. Each year more than 2 million patients are treated using Elekta solutions across 130 countries. Elekta is headquartered in Stockholm, Sweden, with 4,000 employees and offices in more than 40 countries. The company is listed on Nasdaq Stockholm. For more information, visitelekta.com.
